3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
4
Genitourinary
2
CNS
2
Sarcoma
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
47
Breast Neoplasms, Male
5
Neoplasms
4
Neoplasm Metastasis
4
Carcinoma, Ovarian Epithelial
2
Sarcoma
1
Recurrence
1
Pancreatic Neoplasms
1
Pain
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Liver Neoplasms
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Fallopian Tube Neoplasms
1
Colonic Neoplasms
1
Carcinoma
1
Breast Cancer Organoids
1
Bilateral Breast Carcinoma
1
Interventions
pembrolizumab
42
Paclitaxel
26
Cyclophosphamide
25
Carboplatin
23
olaparib
21
Nivolumab
16
fludarabine
15
Docetaxel
13
aldesleukin
12
Gemcitabine
11
Fulvestrant
11
veliparib
9
Bevacizumab
9
sargramostim
8
palbociclib
8
durvalumab
8
Trastuzumab
8
Magnetic Resonance Spectroscopy
8
liposomal doxorubicin
7
atezolizumab
7
Surveys and Questionnaires
7
Ipilimumab
7
Blood Specimen Collection
7
niraparib
6
avelumab
6
Taxes
6
Specimen Handling
6
Interleukin-2
6
Fluorouracil
6
Cisplatin
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
ixabepilone
×
Breast
×
Clear all
NCT00005807
2018-10-09
BMS-247550
Albert Einstein College of Medicine
Phase 1
Completed
40 enrolled